![decoration](/wp-content/themes/yagami-adveris/web/src/img/global/anticorps.png)
![](https://www.minsight-mrd.com/wp-content/uploads/2023/08/ResourcesPublications.webp)
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
Blood-based targeted mass spectrometry (MS) assays have been shown to be at least 1000 times more sensitive than conventional electrophoretic methods. MS-MRD can enable quantitation of disease activity in MM patients with stringent complete remission, while the minimally invasive character of MS-MRD also allows for more frequent sampling. This approach will open ways to treat patients more individually and to optimize the effects of treatment possibilities for MM patients.